Krilogy Financial LLC reduced its position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 14.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 117,276 shares of the company’s stock after selling 19,641 shares during the quarter. Krilogy Financial LLC owned about 0.21% of ARK Genomic Revolution ETF worth $2,761,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in the business. National Bank of Canada FI lifted its stake in shares of ARK Genomic Revolution ETF by 28.4% in the 3rd quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after purchasing an additional 920 shares during the period. IHT Wealth Management LLC bought a new stake in ARK Genomic Revolution ETF in the third quarter valued at about $203,000. Sanctuary Advisors LLC acquired a new position in ARK Genomic Revolution ETF in the second quarter valued at about $222,000. Hilltop Holdings Inc. bought a new position in ARK Genomic Revolution ETF during the third quarter worth about $237,000. Finally, Bridges Investment Management Inc. grew its position in shares of ARK Genomic Revolution ETF by 3.8% during the 2nd quarter. Bridges Investment Management Inc. now owns 14,121 shares of the company’s stock worth $332,000 after buying an additional 517 shares during the period.
ARK Genomic Revolution ETF Price Performance
Shares of ARKG stock opened at $24.14 on Friday. The company has a 50 day moving average of $24.77 and a 200-day moving average of $25.04.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- Overbought Stocks Explained: Should You Trade Them?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Are Dividends? Buy the Best Dividend Stocks
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 01/13 – 01/17
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
